Contact Us

AI for

compliant

faster

compliant

faster

compliant

faster

compliant

faster

compliant

pharma R&D

Entvin AI empowers generic pharma and biologics to bring drugs to market faster using proprietary LLM models.

Book a Demo Call

Trusted by scientists from world’s leading organizations

PROBLEM

The Challenge in Generic R&D Development

Navigating Scattered Information and Time-Intensive Report Writing

Interpreting 100s of documents of RLD data from FDA, EMA, Japan PMDA, Australia TGA, Argentina ANMAT etc.
Analyzing complex patents and reviewing countless peer-reviewed articles.
Drafting comprehensive reports by combining and updating information from multiple sources.

R&D teams spend 60-70% of their time just reading and organizing information rather than innovating. A single comprehensive report can take up to a month to complete

Critical R&D Decisions and Manual DoE challenges

Complex Interdepartmental Coordination during the Development Phase

Navigating Scattered Information and Time-Intensive Report Writing

Interpreting 100s of documents of RLD data from FDA, EMA, Japan PMDA, Australia TGA, Argentina ANMAT etc.
Analyzing complex patents and reviewing countless peer-reviewed articles.
Drafting comprehensive reports by combining and updating information from multiple sources.

R&D teams spend 60-70% of their time just reading and organizing information rather than innovating. A single comprehensive report can take up to a month to complete

Critical R&D Decisions and Manual DoE challenges

Complex Interdepartmental Coordination during the Development Phase

Navigating Scattered Information and Time-Intensive Report Writing

Interpreting 100s of documents of RLD data from FDA, EMA, Japan PMDA, Australia TGA, Argentina ANMAT etc.
Analyzing complex patents and reviewing countless peer-reviewed articles.
Drafting comprehensive reports by combining and updating information from multiple sources.

R&D teams spend 60-70% of their time just reading and organizing information rather than innovating. A single comprehensive report can take up to a month to complete

Critical R&D Decisions and Manual DoE challenges

Complex Interdepartmental Coordination during the Development Phase

Navigating Scattered Information and Time-Intensive Report Writing

Interpreting 100s of documents of RLD data from FDA, EMA, Japan PMDA, Australia TGA, Argentina ANMAT etc.
Analyzing complex patents and reviewing countless peer-reviewed articles.
Drafting comprehensive reports by combining and updating information from multiple sources.

R&D teams spend 60-70% of their time just reading and organizing information rather than innovating. A single comprehensive report can take up to a month to complete

Critical R&D Decisions and Manual DoE challenges

Complex Interdepartmental Coordination during the Development Phase

SOLUTION

Entvin: AI-Powered Drug Development

Automated R&D Report Generation

Compiles comprehensive reports in 30 minutes instead of 3-4 weeks
Intelligently extracts relevant information from documents
Automatically updates reports as new information becomes available

Accelerated Development - Slash months off your development timeline by automating time-consuming report generation and updating processes

Connectors with Global Regulatory and Scientific Data Sources

Integrates with major regulatory databases (FDA, EMA, PMDA, etc.) for real-time updates
Accesses vast scientific literature repositories and patent databases
Provides a unified interface for seamless navigation across diverse data sources

Gain instant access to the most current global regulatory and scientific information, ensuring compliance and informed decision-making

AI-Driven R&D Assistant

Offers data-backed recommendations for literature review
Derive potential stability issues and bioequivalence challenges based on RLD data
Suggests optimal experimental designs based on historical data and current research

Reduce research time during development by leveraging AI chatbot to answer queries and make data-driven decisions

IMPACT

Faster Drug Launches and Superior Research Outcomes

Accelerated ANDA Research

Cut R&D reports creation time from 1 month to just 1-2 days, speeding up ANDA research timelines.

Faster Drug Launch

Increase the likelihood of securing a 180-day exclusivity period, critical for capturing up to 80% of a generic drug's lifetime revenue, adding $10-100Mn per molecule.

Improved Research

Enhance research quality by enabling scientists to concentrate on critical, non-automatable tasks, thereby enhancing scientific outcomes.

Expanded Research Capacity

Empowers R&D teams to scale research efforts, increasing the number of molecules in the pipeline and enhancing approval chances.

NUMBERS

Entvin Empowering Scientists Everyday

6x

Return on Investment

9,000+

Scientists Hours Saved

1.2M+

Data Points Synned Weekly

4700+

Orange Book Molecules

SECURITY

Modern Enterprise Grade Data Security That Pharma Needs

Hyper-Secure Deployment

Hosted securely in a dedicated private cloud environment.

Regulatory Compliance

Certified with SOC2, ISO, HIPAA, and GDPR standards, with regular audits.

Secure User Data

Ensures robust security for user activity logs and data, preserving confidentiality and integrity

TESTIMONIALS

Voices of Innovators

"As a scientist working on complex generics, I'm impressed by Entvin's comprehensive approach. Their tool not only pulls critical parameters from various regulatory and scientific documents but also provides AI-generated insights on excipient compatibility and dissolution methods. This level of analysis typically takes our team weeks to compile manually."

Senior Director

Amneal Pharmaceuticals

"Entvin provides a comprehensive overview of critical RLD parameters by intelligently extracting data from multiple regulatory sources. This level of automation and insight is invaluable for FR&D scientists looking to accelerate their development process."

Scientist, Formulation Development

Biocon

“Entvin has developed an innovative solution that addresses a critical need in the pharmaceutical industry. Their AI-driven approach to literature review is not only time-saving but also provides insights that could lead to more efficient drug development processes. It's exciting to see how this technology could shape the future of pharmaceutical research."

Director

R&D, Cipla

"As a scientist working on biologics, I'm impressed by Entvin's comprehensive approach to aggregating regulatory data. Their AI assistant that can rapidly extract key details from lengthy documents is particularly valuable. With some enhancements to include more peer-reviewed scientific sources, this platform could become an indispensable tool for formulation scientists across the industry."

Senior Scientist

Global Regulatory, Lupin

"Entvin's R&D assistant dramatically reduces the time spent searching through regulatory documents, allowing scientists to focus more on lab work and FR&D."

Director - Formulation Development

Teva Pharmaceuticals

Senior Director

Amneal Pharmaceuticals

Director

R&D, Cipla

Senior Scientist

Global Regulatory, Lupin

Scientist, Formulation Development

Biocon

"Entvin's R&D assistant dramatically reduces the time spent searching through regulatory documents, allowing scientists to focus more on lab work and FR&D."

Director - Formulation Development

Teva Pharmaceuticals

CONTACT US

Connect with our Founders Today

USA

Entvin, Inc. STE 6003, Dover, Delaware, USA- 19904

India

Entvin Labs Pvt. Ltd. No 351 Salarpuria Towers-I, Hosur Road, Koramangala, Bengaluru, Karnataka, India- 560095

Company

Home

Testimonials

Schedule a Call

Product

Problems

Features